Literature DB >> 9822506

Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second- and third-trimester human fetal cord blood hematopoietic stem cells (progenitor cells).

D V Surbek1, W Holzgreve, W Jansen, D Heim, H Garritsen, C Nissen, A Wodnar-Filipowicz.   

Abstract

OBJECTIVE: The aims of this study were (1) to assess the hematopoietic stem cell (progenitor cell) contents of umbilical cord blood samples from second-trimester and early-third-trimester fetuses versus term fetuses and (2) to determine the feasibility of cryopreservation and enrichment of cord blood from fetuses of different gestational ages. STUDY
DESIGN: Cord blood between 13 and 42 weeks' gestation (n = 31) was sampled after delivery or fetal expulsion. Fluorescence-activated cell sorting was used to measure CD34(+) and CD34(+)CD38(-) cell numbers. Samples were cryopreserved with 10% dimethylsulfoxide, and CD34(+) enrichment was performed by magnetically activated cell sorting with the MiniMACS system (Miltenyi Biotech, Bergisch Gladbach, Germany). Kruskal-Wallis analysis of variance and the Mann-Whitney U test were used for analysis of data.
RESULTS: CD34(+) and CD34(+)CD38(-) cell contents were significantly higher in second- and early third-trimester fetuses than in term fetuses (CD34(+) 2.57% +/- 0.38%, 1.48% +/- 0. 31%, and 0.7% +/- 0.13%, respectively, P =.0067; CD34(+)CD38(-) 0. 72% +/- 0.26%, 0.18% +/- 0.05%, and 0.06% +/- 0.02%, respectively, P =.0132). Mononuclear cell recovery, viability, and CD34(+) cell purity after cryopreservation and enrichment were similar among different gestational ages.
CONCLUSION: Cord blood stem cell content decreases significantly from the second trimester to term. Cryopreservation and enrichment of these cells from earlier gestational ages is feasible. This might be especially useful for allogeneic stem cell transplantation and for in utero gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822506     DOI: 10.1016/s0002-9378(98)70137-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Human umbilical cord blood-borne fibroblasts contain marrow niche precursors that form a bone/marrow organoid in vivo.

Authors:  Alice Pievani; Benedetto Sacchetti; Alessandro Corsi; Benedetta Rambaldi; Samantha Donsante; Valeria Scagliotti; Patrizia Vergani; Cristina Remoli; Andrea Biondi; Pamela G Robey; Mara Riminucci; Marta Serafini
Journal:  Development       Date:  2017-03-15       Impact factor: 6.868

2.  Term vs. preterm cord blood cells for the prevention of preterm brain injury.

Authors:  Jingang Li; Tamara Yawno; Amy Sutherland; Jan Loose; Ilias Nitsos; Beth J Allison; Robert Bischof; Courtney A McDonald; Graham Jenkin; Suzanne L Miller
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

3.  Gene expression profile of mesenchymal stem cells from paired umbilical cord units: cord is different from blood.

Authors:  Mariane Secco; Yuri B Moreira; Eder Zucconi; Natassia M Vieira; Tatiana Jazedje; Alysson R Muotri; Oswaldo K Okamoto; Sergio Verjovski-Almeida; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2009-12       Impact factor: 5.739

Review 4.  Design strategies of biodegradable scaffolds for tissue regeneration.

Authors:  Khalil N Bitar; Elie Zakhem
Journal:  Biomed Eng Comput Biol       Date:  2014-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.